Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European Region.
Migliori GB, Korotych O, Achar J, Ciobanu A, Dravniece G, Germanovych M, Gurbanova E, Hovhannesyan A, Khachatryan N, Kuksa L, Lomtadze N, Rich ML, Skrahina A, Yedilbayev A. Migliori GB, et al. Among authors: dravniece g. IJTLD Open. 2024 Mar 1;1(3):103-110. doi: 10.5588/ijtldopen.24.0035. eCollection 2024 Mar. IJTLD Open. 2024. PMID: 38966407 Free PMC article.
Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, Skrahina A, Dravniece G, Kuksa L, Rich M, Khachatryan N, Germanovych M, Kadyrov A, Terleieva I, Akhundova I, Adenov M, Durdyeva M, Kiria N, Parpieva N, Yatskevich N, Jumayev R, Nurov R, Diktanas S, Vilc V, Migliori GB, Yedilbayev A. Korotych O, et al. Among authors: dravniece g. Lancet Infect Dis. 2024 Oct;24(10):1151-1161. doi: 10.1016/S1473-3099(24)00228-7. Epub 2024 Jun 13. Lancet Infect Dis. 2024. PMID: 38880112 Free PMC article.
Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients.
van de Berg SEJ, Pelzer PT, van der Land AJ, Abdrakhmanova E, Ozi AM, Arias M, Cook-Scalise S, Dravniece G, Gebhard A, Juneja S, Handayani R, Kappel D, Kimerling M, Koppelaar I, Malhotra S, Myrzaliev B, Nsa B, Sugiharto J, Engel N, Mulder C, van den Hof S. van de Berg SEJ, et al. Among authors: dravniece g. BMC Public Health. 2021 Jul 16;21(1):1404. doi: 10.1186/s12889-021-11427-y. BMC Public Health. 2021. PMID: 34271884 Free PMC article.
Introducing bedaquiline: experiences from the Challenge TB Project.
Edwards CG, Wares DF, Dravniece G, Gebhard A, Tiemersma E, van der Grinten E, Gidado M, van Weezenbeek K. Edwards CG, et al. Among authors: dravniece g. Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1046-1053. doi: 10.5588/ijtld.19.0790. Int J Tuberc Lung Dis. 2020. PMID: 33126937
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis.
Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, Brode S, Campbell JR, Casas EC, Conradie F, Dravniece G, du Cros P, Falzon D, Jaramillo E, Kuaban C, Lan Z, Lange C, Li PZ, Makhmudova M, Maug AKJ, Menzies D, Migliori GB, Miller A, Myrzaliev B, Ndjeka N, Noeske J, Parpieva N, Piubello A, Schwoebel V, Sikhondze W, Singla R, Souleymane MB, Trébucq A, Van Deun A, Viney K, Weyer K, Zhang BJ, Ahmad Khan F. Abidi S, et al. Among authors: dravniece g. Eur Respir J. 2020 Mar 20;55(3):1901467. doi: 10.1183/13993003.01467-2019. Print 2020 Mar. Eur Respir J. 2020. PMID: 31862767 Free article.
Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences.
Tiemersma E, van den Hof S, Dravniece G, Wares F, Molla Y, Permata Y, Lukitosari E, Quelapio M, Aung ST, Aung KM, Thuy HT, Hoa VD, Sulaimanova M, Sagyndikova S, Makhmudova M, Soliev A, Kimerling M. Tiemersma E, et al. Among authors: dravniece g. Eur Respir Rev. 2019 Oct 11;28(153):180115. doi: 10.1183/16000617.0115-2018. Print 2019 Sep 30. Eur Respir Rev. 2019. PMID: 31604816 Free PMC article. Review.
QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment.
Monedero-Recuero I, Hernando-Marrupe L, Sánchez-Montalvá A, Cox V, Tommasi M, Furin J, Chiang CY, Quelapio M, Koura KG, Trébucq A, Padanilam X, Dravniece G, Piubello A. Monedero-Recuero I, et al. Among authors: dravniece g. Int J Tuberc Lung Dis. 2018 Oct 26. doi: 10.5588/ijtld.18.0423. Online ahead of print. Int J Tuberc Lung Dis. 2018. PMID: 30366516
14 results